Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma".
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has secured exclusive rights to market and distribute Aumolertinib across multiple regions, sourced from China's Hansoh Pharma. Aumolertinib is a third-generation EGFR-TKI (targeted therapy for lung cancer) already approved by the UK's MHRA and China's NMPA. The deal gives Glenmark access to a ready-to-commercialize oncology asset with existing regulatory approvals in key markets. Details of financial terms, specific regions covered, and upfront/milestone payments were not disclosed in this filing. The move signals Glenmark's continued push to strengthen its specialty and oncology portfolio through in-licensing.
Positive for shareholders as it expands Glenmark's oncology pipeline with an already-approved lung cancer drug, potentially accelerating revenue growth in specialty markets. Watch for follow-up filings on deal financials and launch timelines.